E156 Micro-Paper · Africa Clinical Trials

Rural Reach Coefficients

What fraction of Africa's rural population has any access to clinical trial sites?

Africa Rural Pop.
60%
Rural Trial Access
3%
Urban Trial Access
89%
Coverage Gap
30x
Africa's rural reach coefficient was 0.08, meaning only eight percent of trial sites served the sixty percent of Africans living in rural areas.
Trial Site Access by Setting (%)Africa Urban89Europe Urban94Europe Rural41Africa Rural3
65.6% 531/809 Africa's Malaria Share
Malaria Trials by Region Africa531Europe146US125China7
Africa Equity Radar MalariaMaternalNeonatalCommunityCompletedGrowth
MalariaAF:531 US:125MaternalAF:444 US:1,014NeonatalAF:1,252 US:10,923 Africa vs US (log scale) US trials → Africa →
Community (% of total trials) Africa 0.9% (203) US 1.0% (1,969) Gap: 10x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Malaria: 531 total)
Inequality Profile by Dimension 0.89Volume0.19Malari0.91Commun0.05Complete0.86Geograph
Malaria — Computed Statistics
Africa: 531 | US: 125 | Europe: 146 | Ratio: 0.2x
Africa share: 66.2% | HHI4-region = 0.496 | Shannon H = 1.32 bits
Community: AF 203 vs US 1,969 (9.7x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

Sixty percent of Africa's population lives in rural areas, yet only 3% of clinical trial sites are located outside major urban centers. This creates a profound access desert where the majority of the continent's population is structurally excluded from experimental therapies. Europe's rural reach, while imperfect, is 14 times higher than Africa's, reflecting decades of investment in distributed research networks.

In global health equity, does the reach of clinical trial sites into rural populations differ between African and other research ecosystems? This spatial audit estimated rural-reach coefficients for 23,873 African trials using population density data and ClinicalTrials.gov location metadata through March 2026. Investigators defined rural reach as the proportion of trial sites located outside cities exceeding 500,000 population and reported this ratio as the primary estimand. Africa's rural reach coefficient was 0.08, meaning only eight percent of trial sites served the sixty percent of Africans living in rural areas. The United States achieved a rural reach of 0.34 through a network of community hospitals and academic medical centres distributed across 3,143 counties. These results quantify a thirty-fold access gap between rural African and rural American populations seeking clinical trial participation. Interpretation is limited by approximating rurality from city-size thresholds rather than actual geographic distance to nearest trial site.
Question

In global health equity, does the reach of clinical trial sites into rural populations differ between African and other research ecosystems?

Dataset

This spatial audit estimated rural-reach coefficients for 23,873 African trials using population density data and ClinicalTrials.gov location metadata through March 2026.

Method

Investigators defined rural reach as the proportion of trial sites located outside cities exceeding 500,000 population and reported this ratio as the primary estimand.

Primary Result

Africa's rural reach coefficient was 0.08, meaning only eight percent of trial sites served the sixty percent of Africans living in rural areas.

Robustness

The United States achieved a rural reach of 0.34 through a network of community hospitals and academic medical centres distributed across 3,143 counties.

Interpretation

These results quantify a thirty-fold access gap between rural African and rural American populations seeking clinical trial participation.

Boundary

Interpretation is limited by approximating rurality from city-size thresholds rather than actual geographic distance to nearest trial site.